Pharmacologic Stabilization and Management of Acute Heart Failure Syndromes in the Emergency Department

Heart Failure Clinics

Volumn 5, Issue 1, 2009, Pages 43-54

  Kirk, J Douglas ^a   Parissis, John T ^b   Filippatos, Gerasimos ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

Author keywords

Emergency department; Heart failure; Therapeutic options

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUMETANIDE; CAPTOPRIL; DIURETIC AGENT; DOBUTAMINE; DOPAMINE; ENALAPRIL; ENALAPRILAT; FUROSEMIDE; GLYCERYL TRINITRATE; INOTROPIC AGENT; ISOSORBIDE DINITRATE; LEVOSIMENDAN; MILRINONE; MORPHINE; NESIRITIDE; NITRATE; NITROPRUSSIDE SODIUM; PLACEBO; SPIRONOLACTONE; TORASEMIDE; VASOACTIVE AGENT; VASODILATOR AGENT;

ACUTE HEART FAILURE; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; CONTINUOUS INFUSION; CYANIDE POISONING; DRUG DOSE ESCALATION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG OVERDOSE; EMERGENCY CARE; EMERGENCY WARD; HEADACHE; HEART HEMODYNAMICS; HOSPITAL READMISSION; HUMAN; HYPOTENSION; KIDNEY DYSFUNCTION DAVS ORTHOSTATIC HYPOTENSION; LOADING DRUG DOSE; LOW DRUG DOSE; LUNG EDEMA; OUTCOME ASSESSMENT; PATIENT SAFETY; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; TACHYCARDIA;

ALGORITHMS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CARDIOTONIC AGENTS; DIURETICS; EMERGENCY SERVICE, HOSPITAL; HEART FAILURE; HUMANS; NATRIURETIC AGENTS; NATRIURETIC PEPTIDE, BRAIN; NITROGLYCERIN; NITROPRUSSIDE; VASODILATOR AGENTS;

EID: 56049112990     PISSN: 15517136     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hfc.2008.08.003     Document Type: Review

References (63)

1. Gheorghiade M., Zannad F., Sopko G., et al. International working group on acute heart failure syndromes. Acute heart failure syndromes: current state and framework for future research. Circulation 112 (2005) 3958-3968
2. Adams Jr. K.F., Fonarow G.C., Emerman C.L., et al. ADHERE scientific advisory committee and investigators. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J 149 (2005) 209-216
3. Cleland J.G., Swedberg K., Follath F., et al. Study group on diagnosis of the working group on heart failure of the European society of cardiology. The Euroheart failure survey programme-a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. Eur Heart J 24 (2003) 442-463
4. Heart Failure Society Of America. Executive summary: HFSA 2006 comprehensive heart failure practice guideline. J Card Fail 12 (2006) 10-38
5. Nieminen M.S., Böhm M., Cowie M.R., et al. ESC committee for practice guideline (CPG). Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the task force on acute heart failure of the European society of cardiology. Eur Heart J 26 (2005) 384-416
6. De Luca L., Fonarow G.C., Mebazaa A., et al. Early pharmacological treatment of acute heart failure syndromes: a systematic review of clinical trials. Acute Card Care 9 (2007) 10-21
7. Gheorghiade M., De Luca L., Fonarow G.C., et al. Pathophysiologic targets in the early phase of acute heart failure syndromes. Am J Cardiol 96 6A (2005) 11G-17G
8. Sackner-Bernstein J.D., Skopicki H.A., and Aaronson K.D. Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation 111 (2005) 1487-1491
9. Sackner-Bernstein J.D., Kowalski M., Fox M., et al. Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials. JAMA 293 (2005) 1900-1905
10. Zannad F., Mebazaa A., Juillière Y., et al. Clinical profile, contemporary management and one-year mortality in patients with severe acute heart failure syndromes: the EFICA study. Eur J Heart Fail 8 (2006) 697-705
11. Gheorghiade M., Abraham W.T., Albert N.M., et al. Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure. JAMA 296 (2006) 2217-2226
12. Alla F., Zannad F., and Filippatos G. Epidemiology of acute heart failure syndromes. Heart Fail Rev 12 (2007) 91-95
13. Chatti R., Fradj N.B., Trabelsi W., et al. Algorithm for therapeutic management of acute heart failure syndromes. Heart Fail Rev 12 (2007) 113-117
14. Weinfeld M.S., Chertow G.M., and Stevenson L.W. Aggravated renal dysfunction during intensive therapy for advanced chronic heart failure. Am Heart J 138 (1999) 285-290
15. Cooper H.A., Dries D.L., Davis C.E., et al. Diuretics and risk of arrhythmic death in patients with left ventricular dysfunction. Circulation 100 (1999) 1311-1315
16. Jhund P.S., McMurray J., and Davie A.P. The acute vascular effects of furosemide in heart failure. Br J Clin Pharmacol 50 (2000) 9-13
17. Gottlieb S.S., Brater D.C., Thomas I., et al. BG9719 (CVT-124), an A1 adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy. Circulation 105 (2002) 1348-1353
18. Cotter G, Weissgarten J, Metzkor E, et al. Increased toxicity of high-dose furosemide versus low-dose dopamine in the treatment of refractory congestive heart failure. Clin Pharmacol Ther 1997;62:187-93.
19. Cotter G., Metzkor E., Kaluski E., et al. Randomised trial of high-dose isosorbide dinitrate plus low-dose furosemide versus high-dose furosemide plus low-dose isosorbide dinitrate in severe pulmonary oedema. Lancet 351 (1998) 389-393
20. Lahav M., Regev A., Ra'anani P., et al. Intermittent administration of furosemide vs continuous infusion preceded by a loading dose for congestive heart failure. Chest 102 (1992) 725-731
21. Dormans T.P., van Meyel J.J., Gerlag P.G., et al. Diuretic efficacy of high dose furosemide in severe heart failure: bolus injection versus continuous infusion. J Am Coll Cardiol 28 (1996) 376-382
22. Cohn P.F., and Gorlin R. Physiologic and clinical actions of nitroglycerin. Med Clin North Am 58 (1974) 407-415
23. Elkayam U., Bitar F., Akhter M.W., et al. Intravenous nitroglycerin in the treatment of decompensated heart failure: potential benefits and limitations. J Cardiovasc Pharmacol Ther 9 (2004) 227-241
24. Katz S.D., Biasucci L., Sabba C., et al. Impaired endothelium-mediated vasodilation in the peripheral vasculature of patients with congestive heart failure. J Am Coll Cardiol 19 (1992) 918-925
25. Elkayam U., Roth A., Kumar A., et al. Hemodynamic and volumetric effects of venodilation with nitroglycerin in chronic mitral regurgitation. Am J Cardiol 60 (1987) 1106-1111
26. Loh E., Elkayam U., Cody R., et al. A randomized multicenter study comparing the efficacy and safety of intravenous milrinone and intravenous nitroglycerin in patients with advanced heart failure. J Card Fail 7 (2001) 114-121
27. Nashed A.H., and Allegra J.R. Intravenous nitroglycerin boluses in treating patients with cardiogenic pulmonary edema. Am J Emerg Med 13 (1995) 612-613
28. Levy P., Compton S., Welch R., et al. Treatment of severe decompensated heart failure with high-dose intravenous nitroglycerin: a feasibility and outcome analysis. Ann Emerg Med 50 (2007) 144-152
29. Publication Committee for the VMAC Investigators (Vasodilatation in the Management of Acute CHF). Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA 287 (2002) 1531-1540
30. Levin E.R., Gardner D.G., and Samson W.K. Natriuretic peptides. N Engl J Med 339 (1998) 321-328
31. Mills R.M., LeJemtel T.H., Horton D.P., et al. Sustained hemodynamic effects of an infusion of nesiritide (human B-type natriuretic peptide) in heart failure: a randomized, double-blind, placebo-controlled clinical trial. Natrecor study group. J Am Coll Cardiol 34 (1999) 155-162
32. Colucci W.S., Elkayam U., Horton D.P., et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide study group. N Engl J Med 343 (2000) 246-253
33. Guiha N.H., Cohn J.N., Mikulic E., et al. Treatment of refractory heart failure with infusion of nitroprusside. N Engl J Med 291 (1974) 587-592
34. Khot U.N., Novaro G.M., Popović Z.B., et al. Nitroprusside in critically ill patients with left ventricular dysfunction and aortic stenosis. N Engl J Med 348 (2003) 1756-1763
35. Cohn J.N., Franciosa J.A., Francis G.S., et al. Effect of short-term infusion of sodium nitroprusside on mortality rate in acute myocardial infarction complicated by left ventricular failure: results of a Veterans Administration cooperative study. N Engl J Med 306 (1982) 1129-1135
36. Bussmann W.D., and Schupp D. Effect of sublingual nitroglycerin in emergency treatment of severe pulmonary edema. Am J Cardiol 41 (1978) 931-936
37. Fonarow G.C., and Corday E. ADHERE scientific advisory committee. Overview of acutely decompensated congestive heart failure (ADHF): a report from the ADHERE registry. Heart Fail Rev 9 (2004) 179-185
38. Milo-Cotter O., Adams K.F., O'Connor C.M., et al. Acute heart failure associated with high admission blood pressure-a distinct vascular disorder?. Eur J Heart Fail 9 (2007) 178-183
39. Thackray S., Easthaugh J., Freemantle N., et al. The effectiveness and relative effectiveness of intravenous inotropic drugs acting through the adrenergic pathway in patients with heart failure-a meta-regression analysis. Eur J Heart Fail 4 (2002) 515-529
40. Packer M. The search for the ideal positive inotropic agent. N Engl J Med 329 (1993) 201-202
41. Papp Z., Csapó K., Pollesello P., et al. Pharmacological mechanisms contributing to the clinical efficacy of levosimendan. Cardiovasc Drug Rev 23 (2005) 71-98
42. Mebazaa A., Barraud D., and Welschbillig S. Randomized clinical trials with levosimendan. Am J Cardiol 96 (2005) 74G-79G
43. Cleland J.G., Freemantle N., Coletta A.P., et al. Clinical trials update from the American Heart Association: REPAIR-AMI, ASTAMI, JELIS, MEGA, REVIVE-II, SURVIVE, and PROACTIVE. Eur J Heart Fail 8 (2006) 105-110
44. Mebazaa A., Nieminen M.S., Packer M., et al. SURVIVE investigators. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial. JAMA 297 (2007) 1883-1891
45. Munger M.A. Management of acute decompensated heart failure: treatment, controversy, and future directions. Pharmacotherapy 26 (2006) 131S-138S
46. Zannad F., Adamopoulos C., Mebazaa A., et al. The challenge of acute decompensated heart failure. Heart Fail Rev 11 (2006) 135-139
47. Felker G.M., and O'Connor C.M. Inotropic therapy for heart failure: an evidence-based approach. Am Heart J 142 (2001) 393-401
48. Parissis J., Farmakis D., and Nieminen M. Classical inotropes and new cardiac enhancers. Heart Fail Rev 12 (2007) 149-156
49. O'Connor C.M., Gattis W.A., Uretsky B.F., et al. Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: insights from the Flolan International Randomized Survival Trial (FIRST). Am Heart J 138 (1999) 78-86
50. Follath F., Cleland J.G., Just H., et al. Steering committee and investigators of the levosimendan infusion versus dobutamine (LIDO) study. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet 360 (2002) 196-202
51. Cuffe M.S., Califf R.M., Adams Jr. K.F., et al. Outcomes of a prospective trial of intravenous milrinone for exacerbations of chronic heart failure (OPTIME-CHF) investigators. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA 287 (2002) 1541-1547
52. Figgit D.P., Gilles P.S., and Goa K.L. Levosimendan. Drugs 61 (2001) 613-627
53. Perrone S., and Kaplinsky E.J. Calcium sensitizer agents: a new class of inotropic agents in the treatment of decompensated heart failure. Int J Cardiol 103 (2005) 248-255
54. Kivikko M., and Lehtonen L. Levosimendan: a new inodilatory drug for the treatment of decompensated heart failure. Curr Pharm Des 11 (2005) 435-455
55. Parissis J., Filippatos G., Farmakis D., et al. Levosimendan for the treatment of acute heart failure syndromes. Expert Opin Pharmacother 6 15 (2005) 2741-2751
56. DeLuca L., Colucci W., Nieminen M., et al. Evidence-based use of levosimendan in different clinical settings. Eur Heart J 27 (2006) 1908-1920
57. Moiseyev V.S., Põder P., Andrejevs N., et al. Study investigators. Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN). Eur Heart J 23 (2002) 1422-1432
58. Packer M. The randomized multicenter evaluation of intravenous levosimendan efficacy-2 (REVIVE-2) trial. Late-breaking clinical trials. American Heart Association. Presented at the Annual Scientific Session, Dallas (TX), 13-16 November 2005.
59. Peacock W.F., Hollander J.E., Diercks D.B., et al. Morphine and outcomes in acute decompensated heart failure: an ADHERE analysis. Emerg Med J 25 (2008) 205-209
60. Swedberg K., Held P., Kjekshus J., et al. Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. Results of the cooperative new Scandinavian enalapril survival study II (CONSENSUS II). N Engl J Med 327 (1992) 678-684
61. Annane D., Bellissant E., Pussard E., et al. Placebo-controlled, randomized, double-blind study of intravenous enalaprilat efficacy and safety in acute cardiogenic pulmonary edema. Circulation 94 (1996) 1316-1324
62. Pitt B., Zannad F., Remme W.J., et al. For the randomized Aldactone evaluation study investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 341 (1999) 709-717
63. Mebazaa A., Gheorghiade M., Piña I.L., et al. Practical recommendations for prehospital and early in-hospital management of patients presenting with acute heart failure syndromes. Crit Care Med 36 (2008) S129-S139